IL6 and infection: MR studies show—in line with our understanding of biology and our clinical experience with IL-6 inhibition—an increased risk of the incidence of some infections (eg, skin and soft tissue infection, pneumonia) [56] but a reduced risk of severe infections (eg, intensive care admission with sepsis [57], critical COVID-19 [59]).